Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"CAR T cell"”.
-
Development of a canine model to evaluate CAR-T cell subsets
… Immunotherapy with chimeric antigen receptor (CAR) T cells has demonstrated success in human blood cancers, although relapse occurs in ~50% of patients. In the context of solid tumors, CAR-T cells show only transient effects. As a "living therapy", development of the next generation CAR-T cells …
-
Multi-Pronged Approach to Understanding the Toxicity Associated with CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised cancer immunotherapy, providing effective treatment for previously untreatable malignancies. Its success, in treat ment of haematological cancers, is now fast-advancing to solid tumours. Though, these efforts are faced with many …
-
Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment
Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy …
-
Generation of a novel pan-cancer chemokine receptor-modified CAR-T cell therapy directed towards nfP2X7
CAR-T cell therapy has achieved significant success in the treatment of multiple haematological malignancies. However, solid cancers present challenges such as tumour antigen heterogeneity and complex mechanisms of immune evasion that have limited the translation of CAR-T cell therapies from …
-
Exploring Veto Activity: DNAM-1-CD155 Axis in Overcoming NK Cell-Mediated Allo-Rejection and Applications for CAR-T Cell Therapy
… Miller et al. defined veto activity, it enables cells to target host cytotoxic T lymphocyte (CTL) precursors specific to veto cells' antigens, selectively eliminating anti- donor T cell clones without inducing rejection. By leveraging this unique immune property, two key research aims were …
-
Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …
-
Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma
<p>Chimeric antigen receptor (CAR) T cell therapy for glioblastoma remains challenging due to insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, most preclinical studies evaluating CAR T cells in glioblastoma use tumors expressing a single antigen, …
-
Mathematical Modelling of Immuno-Oncology and Related Immunology
… look specifically at Chimeric Antigen Receptor (CAR)-T cell therapy, explore the mechanisms by which this living drug grows and changes inside the body, and explore how and why this process differs so dramatically between patients. </p><p>We develop two ordinary differential equation models -- …
-
Development and characterisation of a novel chimeric antigen receptor against LGR5
… pathway, is lowly expressed in some stem cell niches and overexpressed in multiple cancers, including pre-B acute lymphoblastic leukaemia (pre-B ALL), hepatocellular carcinoma (HCC) and colorectal cancer (CRC). LGR5 has thus emerged as a promising therapeutic target and has spurred the …
-
A three-dimensional agent-based model of glioblastoma with applications towards in vitro and in vivo therapy simulation
… these subtypes lead to downstream differences in cell migration speed and immune system activation status. Despite these behavioral differences, glioblastomas are treated using a uniform standard of care regardless of tumor subtype. To identify subtype-dependent features influencing tumor …
-
A Novel, Codon-Based Approach to Preserve On-Tumor Activity and Reduce Off-Tumor Toxicity of Chimeric Antigen Receptor (CAR) T Cells
<p> Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable results in the treatment of various hematological malignancies, ushering in tremendous innovation within the field of immunotherapy and improving patient outcomes. Despite this, CAR-T cell therapy is associated with a …
-
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies
… responses, about 30%-60% of patients with B-cell malignancies relapse following CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy. Dual antigen targeting could overcome resistance due to antigen escape …
-
The Impact of IL-9 on Disease in Murine Models of Systemic Lupus Erythematosus
… has been shown to have elevated CD4+IL-9+ T cells as well as increased secreted IL-9 and Il9 mRNA compared to healthy controls. In other antibody mediated autoimmune models, such as rheumatoid arthritis, type II innate lymphoid cells (ILC2s) secrete increased IL-9 to promote the suppressive …
-
Development and Evaluation of a Potentially Wearable Device for Circulating Cell Monitoring
Monitoring circulating cells is crucial for assessing cancer metastasis and evaluating the efficacy of chimeric antigen receptor (CAR) T-cell therapies. Traditional blood-draw methods face challenges such as discontinuous monitoring and potential cell degradation, leading to inaccurate estimations. …
-
In-vitro Glioblastoma Treatment Focusing on Convection Enhanced Delivery
… brain cancer with discouraging standard of care. New methods like convection enhanced delivery and chimeric antigen receptor T cells (CAR-T) are promising treatments that can be translated to glioblastoma. In this study, CAR-T cell flow through a hydrogel was explored in the context of …
-
Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive Cell Therapies with Multiple Myeloma
… (MM), a cancer of bone marrow-resident plasma cells, is the 2nd-most common hematological malignancy. However, despite the advent of immunotherapies like chimeric antigen receptor (CAR) -T cells, which gained FDA approval in March 2021, relapse is nearly universally inevitable. The bone marrow …
-
Human Chimeric Antigen Receptor Macrophages For Cancer Immunotherapy
… landmark advances in chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of human cancer, metastatic solid tumors remain an intractable challenge. Myeloid cells are actively recruited to the tumor microenvironment (TME), where tumor associated macrophages (TAMs) are often the …
-
PEDOT:PSS Enhanced Electroporation for Cell Therapy Manufacturing
Cellular immunotherapies, such as chimeric antigen receptor (CAR) T cell therapies and macrophage therapies, have shown promising results in treating a wide range of cancers. Advances in these therapies focus on increasingly complex cellular systems to simultaneously optimize immune cell …
-
Towards a Single Bio-molecule Detector Based on CMOS Nanofluidic Platform
… is a core component of the function of many cell therapy products: It affects the tissue repair capacity of induced Pluripotent Stem Cells (iPSCs) and Mesenchymal Stem cells (MSCs) and the tumorigenicity of Chimeric Antigen Receptor (CAR) T-cell therapies. Ideally, we would be able to …
-
Characterizing T Cell Features of Atypical Lymphocytes for the Optimization of Adoptive Immunotherapies
… results. Two such populations are regulatory T cells (Tregs) and CAR (chimeric antigen receptor-modified) T cells. The functional role of Tregs in the immune system is non-canonical, in that they prevent hyper-inflammation and resolve immunopathology by constraining conventional immune cell …
Page 1 of 2